Editas Medicine, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. The filing was signed February 26, 2021. Editas is a clinical-stage genome-editing company; it has not generated revenue from product sales.
Business context and pipeline
The company develops CRISPR-based in vivo and ex vivo medicines. Its leading clinical programs are EDIT-101 for inherited retinal disease LCA10 and EDIT-301 for sickle cell disease; most other programs remain in research or preclinical development.
- EDIT-101: The first, adult low-dose cohort of the Phase 1/2 BRILLIANCE trial completed dosing in 2020. No severe adverse events or dose-limiting toxicity had been reported in that cohort. Enrollment slowed during the COVID-19 pandemic; dosing in the adult mid-dose cohort began in Q1 2021.
- EDIT-301: FDA cleared the safety portion of the Phase 1/2 RUBY trial in January 2021. A partial clinical hold requires development of a potency assay before the efficacy portion can proceed. The company expected first-subject dosing in 2021 and aimed to submit a beta-thalassemia IND by year-end 2021.
Financial results and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Collaboration and other R&D revenue | $90.7 million | $20.5 million |
| Research and development expense | $158.0 million | $96.9 million |
| General and administrative expense | $67.6 million | $64.6 million |
| Operating loss | $134.8 million | $140.9 million |
| Total other income, net | $18.9 million | $7.2 million |
| Net loss | $116.0 million | $133.7 million |
| Net loss per share, basic and diluted | $1.98 | $2.68 |
| Net cash used in operating activities | $179.8 million | $40.7 million |
- Revenue is collaboration-based, not product revenue. The 2020 increase primarily reflected recognition of previously deferred Allergan revenue following termination of that agreement, plus Juno and other license revenue.
- Cash, cash equivalents and marketable securities totaled $511.8 million at year-end. Working capital was $360.9 million; total assets were $572.6 million and stockholders’ equity was $393.6 million.
- The company reported no conventional debt balance in the presented balance sheet. It had $26.1 million of operating lease liabilities and a $27.5 million noncurrent liability for license-related success payments, settled with shares in January 2021.
- Operating cash use rose substantially year over year. Financing activities provided $224.1 million, mainly from the June 2020 stock offering and option exercises. Investing activities used $140.5 million, primarily reflecting purchases of marketable securities.
- The company stated that year-end liquidity and anticipated interest income were expected to fund operations and capital expenditures into 2023. A January 2021 offering generated approximately $216.9 million net; an additional February 2021 issuance generated approximately $32.6 million net.
Material changes and unusual items
- R&D expense increased 63%, driven by higher external development activity, workforce growth and license-related success payments. G&A expense rose 5%.
- The August 2020 termination of the Allergan collaboration returned global ocular-program rights to Editas but left the company responsible for development costs. Editas made a $20 million termination payment and recognized previously deferred collaboration revenue; no Allergan contract liability remained at year-end.
- Other income included a $16.4 million realized gain from the sale of Beam Therapeutics shares. Equity offerings also increased shares outstanding.
- Quarterly results were uneven: Q3 2020 reported net income of $7.8 million, while Q4 reported a net loss of $62.5 million. These quarterly figures should be interpreted in light of collaboration-revenue timing and unusual items.
- Operating lease obligations totaled $30.2 million in future minimum payments. The company also had contingent license milestones, royalties and success payments not included in that total because timing and achievement were uncertain.
Outlook, risks and contingencies
Management expected losses and significant expenses to continue and did not expect profitability in 2021 or the foreseeable future. It anticipated higher spending as clinical programs advanced and research, staffing and intellectual-property costs continued. Additional financing may be needed; equity financing could dilute shareholders, debt could impose restrictions, and collaborations could require rights or economics to be surrendered.
- Development and regulatory risks include limited human experience with genome editing, trial failure or delay, off-target edits, adverse events, uncertain regulatory standards and manufacturing complexity.
- COVID-19 slowed EDIT-101 enrollment and could disrupt trials, research, manufacturing and financing. The full effect remained uncertain.
- The EDIT-301 potency-assay hold could prevent the efficacy portion of RUBY and collection of efficacy data needed for a future approval application if unresolved.
- CRISPR patent priority, validity and ownership disputes, including USPTO interference proceedings and European patent oppositions, could narrow or undermine licensed rights or require additional licenses.
- Commercial prospects depend on clinical success, manufacturing capacity, patient identification, market acceptance and coverage and reimbursement; gene-editing pricing and reimbursement remain uncertain.
The independent auditor issued an unqualified opinion on the financial statements and internal control over financial reporting. The auditor identified accrued R&D expense estimates as a critical audit matter.
Important facts for investors to verify
- Progress of EDIT-101 enrollment and the timing, content and interpretation of clinical data.
- Development and FDA acceptance of the EDIT-301 potency assay, and whether the partial clinical hold is lifted for the efficacy portion.
- Actual cash consumption, collaboration receipts and whether the stated runway remains adequate as clinical spending rises.
- Recurring versus termination-related collaboration revenue, and the extent to which unusual gains or license payments affect reported results.
- Status and potential financial or program consequences of CRISPR patent disputes and contingent license obligations.